ClinicalTrials.gov
public full text
Public Domain
Efficacy and Safety of SR58611 Compared to Placebo and Paroxetine
Primary objective : * To demonstrate the antidepressant efficacy on the Hamilton Depression Rating Scale of SR58611A 700mg/day compared with placebo in the treatment of patients with a recurrent major depressive episode. Secondary objectives: * To assess the safety profile of SR58611A 700 mg/d in comparison to placebo and to assess plasma concentrations of the active metabolite.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Efficacy and Safety of SR58611A in Patients With Major Depressive Disorder (SIRIUS)#1261694
- A Study Of New Medicine (GSK 372475) For The Treatment Of Depression#1185353
- Controlled-release Paroxetine in Major Depressive Disorder (Double-blind, Placebo-controlled Study)#1008772
- Efficacy and Safety of SR58611A in Patients With Major Depressive Disorder#1280718
- Efficacy and Safety of S 47445 Versus Placebo as Adjunctive Treatment in Depressed Patients Not Fully Recovered From Depressive Symptoms With a Current Antidepressant Treatment#1282090
Record · ID 1371978
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive